The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance

Airway hyperresponsiveness

This observational longitudinal cohort study aims to assess the effect of monoclonal
 antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway
 resistance. The study involves adult participants suffering from dermatological or
 rheumatological illness, who are planning to start treatment with monoclonal antibodies
 targeting interleukin 17 as a part of the treatment of these diseases.
 
 The primary outcome of this study will be changes in airway hyperresponsiveness to
 methacholine challenge reported as response-dose-ratio before and after initiation of
 anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential
 effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for
 measuring changes in FEV1 and Airwave oscillometry.
 
 A reduced degree of airway hyperreactivity and airway resistance after initiating ani-IL-17
 could indicate effectiveness of anti-IL-17 in asthma patients which would have to be examined
 further in a population of asthma patients.